Telmisartan Blocks Advanced Glycation End Product (AGE)-Induced Plasminogen Activator Inhibitor-1 (PAI-1) Gene Expression in Endothelial Cells via Activation of Peroxisome Proliferator-Activated Receptor-? (PPAR-?)

Matsui, Takanori; Nakamura, Kazuo; Takeuchi, Masayoshi; Yamagishi, Sho-ichi
November 2008
Letters in Drug Design & Discovery;Nov2008, Vol. 5 Issue 8, p477
Academic Journal
Advanced glycation end product (AGE) and receptor (RAGE) axis play a central role in the pathogenesis of diabetic vascular complications. Since peroxisome proliferator-activated receptor-? (PPAR-?) agonists have been reported to reduce RAGE gene expression and subsequently suppress the downstream signalings in human umbilical vein endothelial cells (HUVECs), we examined here whether telmisartan, a unique angiotensin II type 1 receptor blocker with PPAR-? agonistic activity, could inhibit the AGE-induced up-regulation of plasminogen activator inhibitor-1 (PAI-1) mRNA levels in HUVECs by suppressing RAGE gene expression. Telmisartan completely blocked the AGE-induced RAGE gene up-regulation in HUVECs, which was partly prevented by GW9662, an inhibitor of PPAR-?. Further, telmisartan was also found to inhibit up-regulation of mRNA levels for PAI-1 in AGE-exposed HUVECs, which was completely prevented by GW9662. These results suggest that telmisartan inhibits the AGE-induced PAI-1 gene induction in HUVECs by down-regulating RAGE expression via PPAR-? activation. Our present study suggests that telmisartan works as an anti-thrombogenic agent against AGEs, which may play a protective role against vascular complications in diabetes.


Related Articles

  • Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase. Yuen, Chi Yung; Wong, Wing Tak; Tian, Xiao Yu; Wong, Siu Ling; Lau, Chi Wai; Yu, Jun; Tomlinson, Brian; Yao, Xiaoqiang; Huang, Yu // Cardiovascular Research;Apr2011, Vol. 90 Issue 1, p122 

    Aims Telmisartan activates peroxisome proliferator-activated receptor-γ (PPARγ) in addition to serving as an angiotensin II type 1 receptor (AT1R) blocker. The PPARγ activity of telmisartan on resistance arteries has remained largely unknown. The present study investigated the...

  • Obesity and Breast Cancer: The Roles of Peroxisome Proliferator-Activated Receptor-? and Plasminogen Activator Inhibitor-1. Carter, Jennifer C.; Church, Frank C. // PPAR Research;2009, Special section p1 

    Breast cancer is the most prominent cancer among females in the United States. There are a number of risk factors associated with development of breast cancer, including consumption of a high-fat diet and obesity. Plasminogen activator inhibitor-1 (PAI-1) is a cytokine upregulated in obesity...

  • Losartan: a study of pharmacovigilance data on 14 522 patients. Mann, R D; Mackay, F; Pearce, G; Freemantle, S; Wilton, L V // Journal of Human Hypertension;Aug99, Vol. 13 Issue 8, p551 

    The objective of this study was to undertake a post-marketing safety surveillance study of losartan, the first specific angiotensin-II receptor antagonist to be marketed in England. It is a non-interventional observational cohort study using the technique of prescription-event monitoring....

  • PPARs in the Control of Uncoupling Proteins Gene Expression. Villarroya, Francesc; Iglesias, Roser; Giralt, Marta // PPAR Research;2007 Special Issue 1, p1 

    Uncoupling proteins (UCPs) are mitochondrial membrane transporters involved in the control of energy conversion in mitochondria. Experimental and genetic evidence relate dysfunctions of UCPs with metabolic syndrome and obesity. The PPAR subtypes mediate to a large extent the transcriptional...

  • Regulation of Sulfotransferase and UDP-Glucuronosyltransferase Gene Expression by the PPARs. Runge-Morris, Melissa; Kocarek, Thomas A. // PPAR Research;2009, Special section p1 

    During phase II metabolism, a substrate is rendered more hydrophilic through the covalent attachment of an endogenous molecule. The cytosolic sulfotransferase (SULT) and UDP-glucuronosyltransferase (UGT) families of enzymes account for the majority of phase II metabolism in humans and animals....

  • Combinatorial roles of nuclear receptors in inflammation and immunity. Glass, Christopher K.; Ogawa, Sumito // Nature Reviews Immunology;Jan2006, Vol. 6 Issue 1, p44 

    Members of the nuclear-receptor superfamily have well-documented regulatory effects on inflammatory processes. Recent work has highlighted the roles of peroxisome-proliferator-activated receptors (PPARs) and liver X receptors (LXRs) in controlling metabolic and inflammatory programmes of gene...

  • Inhibitors of the Protease Domain of Urokinase-Type Plasminogen Activator. Rockway, T.W.; Nienaber, V.; Giranda, V.L. // Current Pharmaceutical Design;Dec2002, Vol. 8 Issue 28, p2541 

    Human urokinase-type plasminogen activator (uPA or uPA) has been implicated in the regulation and control of basement membrane and interstitial protein degradation. Since Urokinase plays a role in tissue remodeling, it may be responsible, in part, for the disease progression of cancer....

  • Medicines Safety Update.  // Australian Prescriber;Jun2012, Vol. 35 Issue 3, p98 

    The article comments on the negative impacts of the exposure to candesartan and other angiotensin II receptor antagonists during pregnancy. It states that exposure to these drugs in pregnancy can cause fetotoxicity and patients who are pregnant should look for an alternative antihypertensive...

  • Comparative safety and tolerability of angiotensin II receptor antagonists. Mazzolai, L.; Burnier, M. // Drug Safety;Jul1999, Vol. 21 Issue 1, p23 

    Hypertension is a very common disease and represents a major risk factor for cardiovascular adverse events such as stroke and heart failure. In recent years, a big effort has been put into detecting and treating patients with hypertension. Several classes of drugs acting by different...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics